Photo from wikipedia
This cohort study assesses whether treatment with glucagon-like peptide-1 (GLP-1) receptor agonists is associated with better outcomes than treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors among patients with type 2 diabetes… Click to show full abstract
This cohort study assesses whether treatment with glucagon-like peptide-1 (GLP-1) receptor agonists is associated with better outcomes than treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors among patients with type 2 diabetes and advanced-stage chronic kidney disease (CKD) or end-stage kidney disease.
Keywords:
dipeptidyl peptidase;
kidney;
glucagon like;
kidney disease;
like peptide
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!